Keywords: Johnson & Johnson, Edurant, AIDS, Tibotec, Pfizer, Sutent, USA, FDA approval, Pancreatic cancer
US FDA approves Johnson & Johnson’s novel AIDS drug Edurant; expands use of Pfizer’s Sutent
Article | 23 May 2011
The US Food and Drug Administration on Friday approved US health care giant Johnson & Johnson’s (NYSE: JNJ) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
